论文部分内容阅读
目的血液循环DNA(cell-free DNA,cfDNA)是循环核酸中的一种,现已证实肿瘤患者外周血中cfDNA的含量增高且具有肿瘤细胞DNA的特征。本研究探讨cfDNA在胰腺肿瘤中的研究进展及其在临床中的应用。方法利用PubMed、Medline等全文数据库,以“循环DNA、胰腺癌”为关键词,检索2011-01-2016-08相关文献。纳入标准:(1)cfDNA监测与胰腺癌;(2)胰腺癌cfDNA临床应用。根据纳入标准,符合分析的文献42篇。结果胰腺癌cfDNA检测作为一种微创、较高特异度的“液体活检”技术,不仅提供了肿瘤特异性的遗传信息的变化,还在临床应用方面有显著意义。可以通过检测胰腺癌患者的cfDNA对疾病进行早期辅助诊断、近期疗效的评价、靶向用药和预后评估等。虽然在标本的处理和提取方面尚需要规范,检测灵敏性有待提高,但希望随着创新性检测技术的发展、检测成本的降低和科研人员的进一步研究,能为疾病的早期诊断和患者的预后提供实质性的帮助。结论 cfDNA在胰腺癌的辅助诊断、评价疗效和预后评估方面有着重要的临床意义和广阔的应用前景。
Purpose The cell-free DNA (cfDNA) is one kind of circulating nucleic acid. It has been confirmed that the content of cfDNA in the peripheral blood of tumor patients is increased and has the characteristics of tumor cell DNA. This study was to investigate the progress of cfDNA in pancreatic tumors and its clinical application. Methods The full-text database such as PubMed and Medline was used to search the literature of “circulating DNA and pancreatic cancer” 2011-01-2016-08. Inclusion criteria: (1) cfDNA monitoring and pancreatic cancer; (2) pancreatic cancer cfDNA clinical application. According to the inclusion criteria, 42 articles were analyzed. Results As a minimally invasive and highly specific “liquid biopsy” technique, cfDNA detection of pancreatic cancer not only provided tumor-specific genetic information, but also had clinical significance. Can be detected by the detection of pancreatic cancer patients cfDNA early diagnosis of the disease, the recent evaluation of efficacy, targeted medication and prognosis assessment. Although there is still a need to standardize the processing and extraction of specimens, the detection sensitivity needs to be improved. However, with the development of innovative detection technologies, the reduction of testing costs and further research by researchers are expected to provide early diagnosis and prognosis of patients Provide substantial help. Conclusion cfDNA has important clinical significance and broad application prospects in the auxiliary diagnosis, evaluation of curative effect and prognosis evaluation of pancreatic cancer.